Endothelium-specific SIRT7 targeting ameliorates pulmonary hypertension through Krüpple-like factor 4 deacetylation
Jin Zhang(Shenzhen University), Baohua Liu(Shenzhen University), Xiaolong Tang(Shenzhen University Health Science Center), Deming Gou(Shenzhen University), Si-Qi Liu(Shenzhen University), Xiaosong Yan(Xi’an Children’s Hospital), Chenzhong Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojing Wu(Renmin Hospital of Wuhan University), Langmei Yang(Shenzhen University), Tong‐You Wade Wei(University of California San Diego), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Wang(Guangzhou Experimental Station), Lei Yang(China Tobacco), Shimin Sun(Jena University Hospital), Qifeng Yang(Qilu Hospital of Shandong University), Yuqin Chen(Fujian Medical University), Yanqin Niu(Shenzhen University)
Cited by 22
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
|Seminars in Cancer Biology|2019|1k